Literature DB >> 22138600

Colonisation and infection due to Enterobacteriaceae producing plasmid-mediated AmpC β-lactamases.

Jesús Rodríguez-Baño1, Elisenda Miró, Macarena Villar, Alicia Coelho, Mónica Gozalo, Nuria Borrell, Germán Bou, M Carmen Conejo, Virginia Pomar, Belén Aracil, Nieves Larrosa, Jesús Agüero, Antonio Oliver, Ana Fernández, Jesús Oteo, Alvaro Pascual, Ferran Navarro.   

Abstract

OBJECTIVES: To investigate the epidemiology and clinical features of infections caused by Enterobacteria producing plasmid-mediated AmpC β-lactamases (pAmpC), which are emerging as a cause of resistance to extended-spectrum cephalosporins.
METHODS: A prospective multicentre cohort of patients with infection/colonisation due to pAmpC-producing Enterobacteriaceae was performed in 7 Spanish hospitals from February throughout July 2009. pAmpCs were characterised by PCR and sequencing.
RESULTS: 140 patients were included; organisms isolated were Escherichia coli (n = 100), Proteus mirabilis (n = 20), Klebsiella pneumoniae (n = 17), and others (n = 3). Overall, 90% had a chronic underlying condition. The acquisition was nosocomial in 43%, healthcare-associated in 41% (14% of those were nursing home residents), and community in 16%. Only 5% of patients had no predisposing feature for infection with multidrug-resistant bacteria. Nineteen percent of patients were bacteraemic. Inappropriate empirical therapy was administered to 81% of bacteraemic patients, who had a crude mortality rate of 48%. The most frequent enzyme was CMY-2 (70%, predominantly in E. coli and P. mirabilis) followed by DHA-1 (19%, predominantly in K. pneumoniae).
CONCLUSION: pAmpC-producing Enterobacteriaceae caused nosocomial, healthcare-associated and community infections mainly in predisposed patients. Invasive infections were associated with high mortality which might be partly related to inappropriate empirical therapy.
Copyright © 2011 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22138600     DOI: 10.1016/j.jinf.2011.11.016

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  19 in total

1.  Prevalence and molecular epidemiology of acquired AmpC β-lactamases and carbapenemases in Enterobacteriaceae isolates from 35 hospitals in Spain.

Authors:  E Miró; J Agüero; M N Larrosa; A Fernández; M C Conejo; G Bou; J J González-López; N Lara; L Martínez-Martínez; A Oliver; B Aracil; J Oteo; A Pascual; J Rodríguez-Baño; L Zamorano; F Navarro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-09-07       Impact factor: 3.267

Review 2.  Clinical management of infections caused by multidrug-resistant Enterobacteriaceae.

Authors:  Mercedes Delgado-Valverde; Jesús Sojo-Dorado; Alvaro Pascual; Jesús Rodríguez-Baño
Journal:  Ther Adv Infect Dis       Date:  2013-04

3.  Trends of isolation of intrinsically resistant to colistin Enterobacteriaceae and association with colistin use in a tertiary hospital.

Authors:  G Samonis; I P Korbila; S Maraki; I Michailidou; K Z Vardakas; D Kofteridis; D Dimopoulou; V K Gkogkozotou; M E Falagas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-04-15       Impact factor: 3.267

4.  Phenotypic detection of plasmid-acquired AmpC in Escherichia coli--evaluation of screening criteria and performance of two commercial methods for the phenotypic confirmation of AmpC production.

Authors:  P Edquist; M Ringman; B O Liljequist; K T Wisell; C G Giske
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-04-03       Impact factor: 3.267

5.  Antibiotic resistance in the invasive bacteria Escherichia coli.

Authors:  Viera Lovayová; Katarína Čurová; Vladimír Hrabovský; Mária Nagyová; Leonard Siegfried; Annamaria Toporová; Kvetoslava Rimárová; Štefánia Andraščíková
Journal:  Cent Eur J Public Health       Date:  2022-06       Impact factor: 1.154

6.  Community-onset Escherichia coli infection resistant to expanded-spectrum cephalosporins in low-prevalence countries.

Authors:  Benjamin A Rogers; Paul R Ingram; Naomi Runnegar; Matthew C Pitman; Joshua T Freeman; Eugene Athan; Sally M Havers; Hanna E Sidjabat; Mark Jones; Earleen Gunning; Mary De Almeida; Kaylene Styles; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191

Review 7.  [Systemic therapy with anti-infective agents. Principles of rational use of systemic antibiotics in dermatology].

Authors:  C Sunderkötter; R Brehler; K Becker
Journal:  Hautarzt       Date:  2014-02       Impact factor: 0.751

8.  Association of antibiotic resistance with SHV-12 extended-spectrum β-lactamase in Enterobacter cloacae.

Authors:  Jun Liu; Guo-Ming Li; Li-Yao Lin; Xia-Lei Wu; Shao-Long Huang; Yong Zhou; Zu-Guo Zhao
Journal:  Exp Ther Med       Date:  2015-11-10       Impact factor: 2.447

9.  Epidemiological and clinical complexity of amoxicillin-clavulanate-resistant Escherichia coli.

Authors:  Jesús Rodríguez-Baño; Jesús Oteo; Adriana Ortega; Macarena Villar; M Carmen Conejo; Germán Bou; Maitane Aranzamendi-Zaldumbide; Emilia Cercenado; Mercè Gurguí; Luis Martínez-Martínez; María Merino; Alba Rivera; Antonio Oliver; Irene Weber; Alvaro Pascual; Rosa M Bartolomé; Juan José Gónzalez-López; José Campos
Journal:  J Clin Microbiol       Date:  2013-05-01       Impact factor: 5.948

10.  Detection and occurrence of plasmid-mediated AmpC in highly resistant gram-negative rods.

Authors:  E Ascelijn Reuland; John P Hays; Denise M C de Jongh; Eman Abdelrehim; Ina Willemsen; Jan A J W Kluytmans; Paul H M Savelkoul; Christina M J E Vandenbroucke-Grauls; Nashwan al Naiemi
Journal:  PLoS One       Date:  2014-03-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.